Listen

Press releases

Receive e-mail alerts

Interne link ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen Data Through the Association for Research in Vision and Ophthalmology (ARVO)
juni 08, 2020 om 11:00 AM UTC
Interne link ProQR Announces Annual Meeting of Shareholders
mei 25, 2020 om 11:00 AM UTC
Interne link ProQR Announces First Quarter 2020 Operating and Financial Results
mei 07, 2020 om 11:00 AM UTC
Interne link ProQR Announces Positive Findings From an Interim Analysis in the Phase 1/2 trial of QR-421a for Usher Syndrome and Provides Business Update
maart 31, 2020 om 10:00 AM UTC
Interne link ProQR to Present Findings from Phase 1/2 Interim Analysis of QR-421a for Usher Syndrome
maart 25, 2020 om 08:15 PM UTC
Interne link ProQR Announces Fourth Quarter and Full Year 2019 Results and Provides Business Update
februari 26, 2020 om 12:00 PM UTC
Interne link ProQR to Present at Cowen and Company 40th Annual Health Care Conference
februari 24, 2020 om 12:00 PM UTC
Interne link ProQR Therapeutics Teams Up with the Foundation Fighting Blindness and Blueprint Genetics to Support the My Retina Tracker® Program for People Living with Inherited Retinal Diseases
februari 06, 2020 om 12:00 PM UTC
Interne link ProQR Receives Rare Pediatric Disease Designation from FDA for QR-421a
januari 30, 2020 om 12:00 PM UTC
Interne link ProQR Announces First Patient Dosed in Phase 1/2 Aurora Trial of QR-1123 for Autosomal Dominant Retinitis Pigmentosa
december 11, 2019 om 12:00 PM UTC
Interne link ProQR Receives Orphan Drug Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa
november 21, 2019 om 12:00 PM UTC
Interne link ProQR to Present at Upcoming Scientific Conferences
november 18, 2019 om 12:23 PM UTC
Interne link ProQR to Present at Upcoming Investor Conferences
november 13, 2019 om 12:00 PM UTC
Interne link ProQR Announces Recent Progress and Financial Results for the Third Quarter of 2019
november 06, 2019 om 12:00 PM UTC
Interne link ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares
oktober 18, 2019 om 12:20 PM UTC
Interne link ProQR Prices $50 Million Underwritten Public Offering of Ordinary Shares
oktober 16, 2019 om 03:17 AM UTC
Interne link ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares
oktober 15, 2019 om 09:15 PM UTC
Interne link ProQR Receives Rare Pediatric Disease Designation from FDA for Sepofarsen for the Treatment of LCA10
oktober 15, 2019 om 08:08 PM UTC
Interne link ProQR annonce des premiers résultats positifs pour l'essai de phase 1/2 du sepofarsen chez des patients souffrant d'ACL10
oktober 11, 2019 om 10:02 AM UTC
Interne link ProQR Announces Positive Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients
oktober 10, 2019 om 10:00 AM UTC
Interne link ProQR to Present Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients ahead of AAO
oktober 07, 2019 om 11:00 AM UTC
Interne link ProQR to Present at Two Investor Conferences in October
september 30, 2019 om 11:00 AM UTC
Interne link ProQR Receives Fast Track Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa
september 09, 2019 om 11:00 AM UTC
Interne link ProQR Announces Clearance of IND to Start Clinical Trial of QR-1123 in Patients with Autosomal Dominant Retinitis Pigmentosa (adRP)
augustus 12, 2019 om 11:00 AM UTC
Interne link ProQR Announces Financial Results for the Second Quarter of 2019
augustus 07, 2019 om 11:00 AM UTC

Press releases

Interne link ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen Data Through the Association for Research in Vision and Ophthalmology (ARVO)

Interne link ProQR Announces Annual Meeting of Shareholders

Interne link ProQR Announces First Quarter 2020 Operating and Financial Results

Interne link ProQR Announces Positive Findings From an Interim Analysis in the Phase 1/2 trial of QR-421a for Usher Syndrome and Provides Business Update

Interne link ProQR to Present Findings from Phase 1/2 Interim Analysis of QR-421a for Usher Syndrome

Interne link ProQR Announces Fourth Quarter and Full Year 2019 Results and Provides Business Update

Interne link ProQR to Present at Cowen and Company 40th Annual Health Care Conference

Interne link ProQR Therapeutics Teams Up with the Foundation Fighting Blindness and Blueprint Genetics to Support the My Retina Tracker® Program for People Living with Inherited Retinal Diseases

Interne link ProQR Receives Rare Pediatric Disease Designation from FDA for QR-421a

Interne link ProQR Announces First Patient Dosed in Phase 1/2 Aurora Trial of QR-1123 for Autosomal Dominant Retinitis Pigmentosa

Interne link ProQR Receives Orphan Drug Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa

Interne link ProQR to Present at Upcoming Scientific Conferences

Interne link ProQR to Present at Upcoming Investor Conferences

Interne link ProQR Announces Recent Progress and Financial Results for the Third Quarter of 2019

Interne link ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares

Interne link ProQR Prices $50 Million Underwritten Public Offering of Ordinary Shares

Interne link ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares

Interne link ProQR Receives Rare Pediatric Disease Designation from FDA for Sepofarsen for the Treatment of LCA10

Interne link ProQR annonce des premiers résultats positifs pour l'essai de phase 1/2 du sepofarsen chez des patients souffrant d'ACL10

Interne link ProQR Announces Positive Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients

Interne link ProQR to Present Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients ahead of AAO

Interne link ProQR to Present at Two Investor Conferences in October

Interne link ProQR Receives Fast Track Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa

Interne link ProQR Announces Clearance of IND to Start Clinical Trial of QR-1123 in Patients with Autosomal Dominant Retinitis Pigmentosa (adRP)

Interne link ProQR Announces Financial Results for the Second Quarter of 2019